Company
Every investor coverage indicates participated in a round Endoluminal Sciences raised.
Companies Endoluminal Sciences acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Endoluminal Sciences. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian medtech Endoluminal Sciences has licensed its technology for sealing leaks around artificial heart valves to Swiss valve maker Symetis for use in transcatheter valve products; backers of both companies are named.
Two medical technology companies, Elastagen and Endoluminal Sciences, together received $4.5 million from the NSW Government's Medical Devices Fund, a competitive program backing local medical device development and commercialisation.